Search hospitals > Nevada > Las Vegas
OptumCare Cancer Care at Fort Apache
Claim this profileLas Vegas, Nevada 89148
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
217 reported clinical trials
2 medical researchers
Summary
OptumCare Cancer Care at Fort Apache is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. OptumCare Cancer Care at Fort Apache is involved with conducting 217 clinical trials across 365 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
135 reported clinical trials
214 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation6 years of reported clinical research
Expert in Tumors
Expert in Leukemia
51 reported clinical trials
108 drugs studied
Clinical Trials running at OptumCare Cancer Care at Fort Apache
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Tumors
Prostate Cancer
Gastric Cancer
Renal Cell Carcinoma
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at OptumCare Cancer Care at Fort Apache?
OptumCare Cancer Care at Fort Apache is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. OptumCare Cancer Care at Fort Apache is involved with conducting 217 clinical trials across 365 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.